問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Infectious Disease

更新時間:2023-09-19

黃崇豪Huang, Chung-Hao
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 13 years 3 個月

篩選

List

40Cases

2025-09-01 - 2029-12-31

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age
  • Condition/Disease

    Healthy

  • Test Drug

    注射劑 注射劑

Participate Sites
6Sites

Recruiting6Sites

2025-03-31 - 2028-06-30

Active
A retrospective, observational post-marketing study evaluating the efficacy and safety of intravenously administered polymyxin B and colistin methanesulfonate in treating patients with carbapenem-resistant, Gram-negative bacterial infections.
  • Condition/Disease

    1. Clinical response rate of the polymyxin B group assessed by infection site and infectious pathogen at TOC (End of Treatment (EOT) + 7 days). 2. Clinical response rate of the two treatment groups at TOC. 3. Microbiological response rate of the polymyxin B group assessed by infection site and infectious pathogen at TOC. 4. Microbiological response rate of the two treatment groups at TOC. 5. All-cause mortality rate of the two treatment groups at day 28. 6. Infection-related mortality rate of the two treatment groups at day 28.

  • Test Drug

    POLYMYXIN B SULFATE

Participate Sites
13Sites

Recruiting13Sites

2025-04-01 - 2027-11-30

Not yet recruiting
A randomized, double-blind, placebo-controlled phase 3 trial is investigating the use of VE303 for the prevention of recurrent Clostridium difficile infection.
  • Condition/Disease

    Double-blind, placebo-controlled trial: Proportion of participants with laboratory-confirmed CDI recurrence by week 8

  • Test Drug

    VE303

Participate Sites
3Sites

Recruiting3Sites

2023-12-08 - 2024-09-30

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-05-01 - 2023-05-17

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

2026-06-01 - 2028-12-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

2025-12-01 - 2029-01-04

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2023-03-10 - 2024-11-14

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

2025-01-01 - 2031-01-26

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2031-01-26

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4